文献速递心律失常

消费者主导的房颤筛查:AF-SCREEN国际协作组前沿综述

Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration.
PubMed 文献 · Circulation · 2022-11-07

AF-SCREEN国际协作组评述消费者主导的房颤筛查:尽管可穿戴设备可直接向消费者营销,但医疗专业人员主导的随机对照试验使用多次心电图或连续监测筛查房颤未能显著降低卒中。消费者主导筛查或可提高房颤早期诊断并促进综合管理,但能否降低卒中仍不确定,需等待以临床结局为终点的大型试验结果。

要点

  • 消费者主导的房颤筛查能否降低卒中尚不确定,需等待以临床结局为终点的大型试验。
  • 光电容积脉搏波提示房颤必须经心电图确认,所有消费者发起的记录需专业人员复核。
  • 该筛查在年轻早期使用者中用于卒中预防可能不具成本效益,需在高卒中风险老年人中验证。

核心结论

  • 消费者主导的房颤筛查能否降低卒中仍不确定,医疗专业人员不应在大型结局试验结果公布前支持广泛采用。

研究设计与样本

  • AF-SCREEN国际协作组开展的前沿综述,对消费者主导房颤筛查领域进行批判性评估。

主要发现

  • 医疗专业人员主导的随机对照试验使用多次心电图记录或连续心电图监测检测房颤,未能证明卒中显著减少。
  • 消费者主导的房颤筛查可能提高房颤早期诊断并促进综合管理,包括适当抗凝、心率或节律管理及危险因素干预。
  • 房颤筛查的诊断率通常随筛查次数、持续时间和时间分散度增加而提高,但其预后重要性可能低于单时间点筛查发现的房颤。
  • 单时间点筛查发现的房颤主要为永久性、持续性或高负荷阵发性房颤。
  • 消费者主导的房颤筛查在主要为年轻早期采用者中用于卒中预防可能不具成本效益。

关键数值与推荐

  • 消费者发起的提示可能房颤的心电图记录,始终需要由具备心电图判读经验的医疗专业人员确认。
  • 基于光电容积脉搏波的房颤怀疑必须经心电图确认。
  • 营销房颤筛查设备的公司应报告产品在高危和低危人群中的准确性和性能,除非随机临床试验证明改善,否则应避免声称临床结局获益。
  • 需要在卒中风险较高的老年人中开展研究以证明有效性和成本效益。
  • 公司直接与消费者互动在数据隐私及消费者应用和设备注册方面造成新的监管空白。

临床怎么用

  • 消费者发起的提示房颤的心电图记录需由有经验的医疗专业人员复核确认。
  • 光电容积脉搏波提示房颤时必须经心电图确认。
  • 对消费者主导筛查发现的房颤,应纳入适当抗凝、心率或节律管理及危险因素干预的综合管理。

局限性

  • 消费者主导的房颤筛查能否降低卒中仍不确定。
  • 医疗专业人员主导的随机对照试验未能证明卒中显著减少。
  • 消费者主导筛查在年轻早期采用者中可能不具成本效益,需在高卒中风险老年人中验证有效性和成本效益。
  • 公司直接与消费者互动在数据隐私和设备注册方面造成新的监管空白。
  • 需等待以临床结局为终点的大型进行中试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The technological evolution and widespread availability of wearables and handheld ECG devices capable of screening for atrial fibrillation (AF), and their promotion directly to consumers, has focused attention of health care professionals and patient organizations on consumer-led AF screening. In this Frontiers review, members of the AF-SCREEN International Collaboration provide a critical appraisal of this rapidly evolving field to increase awareness of the complexities and uncertainties surrounding consumer-led AF screening. Although there are numerous commercially available devices directly marketed to consumers for AF monitoring and identification of unrecognized AF, health care professional-led randomized controlled studies using multiple ECG recordings or continuous ECG monitoring to detect AF have failed to demonstrate a significant reduction in stroke. Although it remains uncertain if consumer-led AF screening reduces stroke, it could increase early diagnosis of AF and facilitate an integrated approach, including appropriate anticoagulation, rate or rhythm management, and risk factor modification to reduce complications. Companies marketing AF screening devices should report the accuracy and performance of their products in high- and low-risk populations and avoid claims about clinical outcomes unless improvement is demonstrated in randomized clinical trials. Generally, the diagnostic yield of AF screening increases with the number, duration, and temporal dispersion of screening sessions, but the prognostic importance may be less than for AF detected by single-time point screening, which is largely permanent, persistent, or high-burden paroxysmal AF. Consumer-initiated ECG recordings suggesting possible AF always require confirmation by a health care professional experienced in ECG reading, whereas suspicion of AF on the basis of photoplethysmography must be confirmed with an ECG. Consumer-led AF screening is unlikely to be cost-effective for stroke prevention in the predominantly young, early adopters of this technology. Studies in older people at higher stroke risk are required to demonstrate both effectiveness and cost-effectiveness. The direct interaction between companies and consumers creates new regulatory gaps in relation to data privacy and the registration of consumer apps and devices. Although several barriers for optimal use of consumer-led screening exist, results of large, ongoing trials, powered to detect clinical outcomes, are required before health care professionals should support widespread adoption of consumer-led AF screening.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Brandes, Stavrakis, Freedman, et al. Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration. Circulation. 2022. PMID: 36343103. doi:10.1161/CIRCULATIONAHA.121.058911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。